How big is the North America Oral Anti-Diabetic Drug Market?

The North America Oral Anti-Diabetic Drug Market size is expected to reach USD 18.76 billion in 2024 and grow at a CAGR of 4.70% to reach USD 23.60 billion by 2029. Read More

What is the current North America Oral Anti-Diabetic Drug Market size?

In 2024, the North America Oral Anti-Diabetic Drug Market size is expected to reach USD 18.76 billion. Read More

Who are the key players in North America Oral Anti-Diabetic Drug Market?

Sanofi, Novo Nordisk A/S, AstraZeneca, Pfizer Inc. and Novartis AG are the major companies operating in the North America Oral Anti-Diabetic Drug Market. Read More

What years does this North America Oral Anti-Diabetic Drug Market cover, and what was the market size in 2023?

In 2023, the North America Oral Anti-Diabetic Drug Market size was estimated at USD 17.88 billion. The report covers the North America Oral Anti-Diabetic Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the North America Oral Anti-Diabetic Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

North America Oral Anti-Diabetic Drug Market Share

Statistics for the 2023 & 2024 North America Oral Anti-Diabetic Drug market share, created by Mordor Intelligence™ Industry Reports. North America Oral Anti-Diabetic Drug share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of North America Oral Anti-Diabetic Drug Industry

The North American oral anti-diabetes drug market is semi-consolidated, with a few major manufacturers, such as Eli Lilly and Company, AstraZeneca, Sanofi, and Janssen Pharmaceuticals, having a global market presence. In contrast, the remaining manufacturers are confined to other local or regional markets. Companies are focusing on innovations in drugs for diabetes.